How profitable is Humacyte Inc. (HUMA)?

In FY 2025 (10-K), HUMA converted $2.0M of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / HUMA / financials

OTLK (35) AVXL (32) ARMP (32) VYGR (15) ⌘ Pro Terminal →

Humacyte Inc. (HUMA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.41 -12.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.40

Humacyte Inc. (HUMA) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $114.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HUMA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HUMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Humacyte Inc. (NASDAQ: HUMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.41 (-12.47% 1D, market cap $114.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HUMA ranks #800 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HUMA compare to OTLK and AVXL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HUMA carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, OTLK (Outlook Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $114.0M) and AVXL (Anavex Life Sciences Corp.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $110.3M). Among the 5-stock peer group, HUMA leads on earnings multiple (N/A) while HUMA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HUMA?

▼

Per HUMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818382), Humacyte Inc. generated $2.0M in revenue (-99.4% YoY), -$40.8M in net income, and -$105.9M in free cash flow against $116.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.40 (-2.43%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HUMA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY HUMA SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.36+13.9% Next Q

Q2 (-2Q)

Grade E$0.41+9.8% Next Q

Q3 (-1Q)

Grade E$0.45-8.9% Next Q

Current

Grade E$0.41-9.6% Hist 90D α

Trajectory: E (22) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HUMA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HUMA currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.52) and Max Pain ($0.43) forces dealer call-delta covering toward $1.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HUMA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HUMA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How HUMA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $280.1M

FY24

Rev $320.3M

FY25

Rev $2.0M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$2.0M	-50%	-80%	-$40.8M	-$105.9M	-45%
FY 2024	$320.3M	8%	-35.7%	-$148.7M	-$99.7M	-45%
FY 2023	$280.1M	8%	-35.7%	-$110.8M	-$73.3M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HUMA)

✓Walkthrough of HUMA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HUMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.91%⚡ TESTING RESISTANCE

2026-11-03O $0.47H $0.47L $0.41C $0.41VOL 5.12M

RES: $0.50SUP: $0.27SMA50: $0.52SMA200: $0.80

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HUMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HUMA Butterfly Map → + Track HUMA →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -99.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HUMA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HUMA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HUMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HUMA)

Health Care Rank #800 of 1015 ⚔️ OTLK vs HUMA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HUMA vs. OTLK, AVXL, ARMP, VYGR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Humacyte Inc. (HUMA) ranks #800 by composite RQD confidence (30/100, grade E) and #632 by equity capitalization ($114.2M). Within this direct 5-issuer industry benchmark cohort, HUMA leads on earnings valuation at N/A trailing P/E, while HUMA leads on capital efficiency and profitability with -35.0% ROIC and -30.0% gross margin. OTLK currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with HUMA at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HUMA ACTIVE Humacyte Inc.	E	30/100	—	-30.0%	-35.0%	-12.47%	$114.2M	Benchmark Subject
OTLK Outlook Therapeutics Inc.	D-	35/100	—	4.0%	-35.0%	-5.15%	$114.0M	/otlk-vs-huma →
AVXL Anavex Life Sciences Corp.	E	32/100	—	—	-35.0%	-8.46%	$110.3M	/avxl-vs-huma →
ARMP Armata Pharmaceuticals Inc.	E	32/100	—	—	-35.0%	+0.92%	$122.0M	/armp-vs-huma →
VYGR Voyager Therapeutics Inc.	E	15/100	—	—	-35.0%	-2.27%	$106.0M	/vygr-vs-huma →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818382 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Humacyte Inc. (HUMA) reported GAAP revenue of $2.0M (-99.4% vs. FY2024 revenue of $320.3M , and -99.3% cumulative change since FY2023) , GAAP net income of -$40.8M, operating cash flow of -$105.0M, and free cash flow of -$105.9M (-6.3% YoY). On the balance sheet, HUMA closed FY2025 with $116.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.0M	-$40.8M	-$105.0M	-$105.9M	$116.4M	—
FY2024 (FY)	2024-12-31	$320.3M	-$148.7M	-$98.1M	-$99.7M	$137.9M	—
FY2023 (FY)	2023-12-31	$280.1M	-$110.8M	-$73.3M	-$73.3M	—	—

3. HUMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HUMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HUMA compare to OTLK and AVXL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HUMA?

Where is HUMA trading relative to its 50-day, 200-day, and 52-week technical levels?

HUMA last traded at $0.41 (-12.47% on volume of 5,119,893 shares), positioning the stock -21.15% below its 50-day simple moving average ($0.52) and -48.75% below its 200-day simple moving average ($0.80). Across its 52-week range of $0.34 to $1.68, HUMA sits at the 5.2% percentile with a 14-day RSI of 43.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.46).

Direct Sub-Reports: HUMA RQD Cockpit HUMA 12M Forecast HUMA Earnings & Move HUMA Dividends & DRIP HUMA Insiders & 13F HUMA Whale Options HUMA Profit Sankey HUMA News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

HUMA — Humacyte Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Humacyte Inc. (HUMA) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.41 (-12.47% 1D, market capitalization $114.2M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (5/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Humacyte Inc. (HUMA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The market capitalization is $0.1B. FY 2025 revenue was $2.0M. — describes its specific products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Humacyte Inc. (HUMA) reported $2.0M in annual revenue (up from $320.3M in FY2024, -99.4% YoY) and -$40.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($280.1M revenue, -$110.8M net income) through FY2025, HUMA scaled operating cash flow to -$105.0M and free cash flow to -$105.9M, backed by $116.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.34 – $1.68 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level context available is the Health Care classification and the beta of 1.0.

Key Question #1: Can HUMA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $2.0M and free cash flow of -$105.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is HUMA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HUMA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Humacyte Inc. (HUMA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HUMA Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 1d ago

Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts

Yahoo Finance report covering Humacyte Inc. (HUMA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade

Yahoo Finance report covering Humacyte Inc. (HUMA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Humacyte stock price target reiterated at $1 by StoneX on demand

Investing.com report covering Humacyte Inc. (HUMA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Humacyte(HUMA) Stock Options Chain | Quotes & News

Moomoo report covering Humacyte Inc. (HUMA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 1d ago

49 hospitals ordered a bioengineered blood vessel. Several surgeons submitted patient case studies for presentations.

Stock Titan report covering Humacyte Inc. (HUMA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Humacyte stock gains ordering hospitals, H.C. Wainwright reiterates Buy

Investing.com report covering Humacyte Inc. (HUMA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.debelegger.nl • 1d ago

Humacyte (HUMA) Stock Price, Chart & Analysis

www.debelegger.nl report covering Humacyte Inc. (HUMA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Yahoo Finance report covering Humacyte Inc. (HUMA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HUMA Bull vs. Bear Conversation Board — What's Your Call at $0.41?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HUMA 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $0.48 (+17.1%)

📌 Pinned Debate

The news wire reports 49 hospitals ordering the bioengineered blood vessel, with H.C. Wainwright reiterating a Buy.

Here is why I am bullish on HUMA here at $0.41: The news wire reports 49 hospitals ordering the bioengineered blood vessel, with H.C. Wainwright reiterating a Buy.. Compare HUMA's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $0.39 are getting bought.

RetailWhale_TX 🐂 BULL

Both sides have a point here — HUMA's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.35 (-14.6%)

Spot @ $0.41

FY 2025 free cash flow of -$105.9M against $50.5M in cash, with an RQD score of 31 and a Piotroski F-Score of 2/9.

I respect the product at Humacyte Inc., but the stock at $0.41 is a different story. FY 2025 free cash flow of -$105.9M against $50.5M in cash, with an RQD score of 31 and a Piotroski F-Score of 2/9.. FCF yield is 0.0% and RQD sits at 30/100 (E) — why pay up here when you can wait for next quarter's numbers?